• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

缺氧诱导的人肺癌细胞中促血管生成组织因子表达的调控。

Regulation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells.

机构信息

Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Centrum für Herz- und Kreislaufmedizin, D-12200 Berlin, Germany.

出版信息

Oncol Rep. 2013 Jul;30(1):462-70. doi: 10.3892/or.2013.2413. Epub 2013 Apr 22.

DOI:10.3892/or.2013.2413
PMID:23604472
Abstract

Alternative splicing is a key regulatory mechanism for cellular metabolism controlling cell proliferation and angiogenesis, both of which are crucial processes for tumorigenesis under hypoxia. Human cells express two tissue factor (TF) isoforms, alternatively spliced TF (asTF) and 'full length' TF (flTF). flTF is the major source of thrombogenicity whereas, the function of soluble asTF, particularly in cancer, is widely unknown. In the present study, we examined the impact of alternative splicing on the pro-angiogenic potential and the TF expression pattern of A549 cells under hypoxia. We focused our efforts toward alternative splicing factors, such as Clk1, and pro-angiogenic proliferation-regulating factors, such as Cyr61. We further examined the influence of asTF overexpression on the expression of MCP-1, Cyr61 and VEGF, as well as on cell number and pro-angiogenic properties of A549 cells. Notably, we found hypoxia to induce the expression of alternative splicing factors (Clk1 and Clk4) as well as proliferation- and angiogenesis-promoting factors (Cyr61 and flTF). asTF overexpression in A549 cells also increased both cell number and tube formation. These effects were mediated by the induction of Cyr61, MCP-1 and VEGF, as well as by integrin α(v)β(3). Taken together, our results suggest that the pro-angiogenic potential of A549 lung cancer cells is modulated under hypoxic conditions via modulation of TF isoform expression which in turn is controlled by alternative splicing.

摘要

选择性剪接是细胞代谢的关键调节机制,控制细胞增殖和血管生成,这两者都是缺氧条件下肿瘤发生的关键过程。人体细胞表达两种组织因子(TF)异构体,即选择性剪接 TF(asTF)和“全长” TF(flTF)。flTF 是血栓形成的主要来源,而可溶性 asTF 的功能,特别是在癌症中,广泛未知。在本研究中,我们研究了缺氧下 A549 细胞中选择性剪接对促血管生成潜力和 TF 表达模式的影响。我们专注于选择性剪接因子,如 Clk1,和促血管生成增殖调节因子,如 Cyr61。我们进一步研究了 asTF 过表达对 MCP-1、Cyr61 和 VEGF 的表达、A549 细胞数量和促血管生成特性的影响。值得注意的是,我们发现缺氧诱导了选择性剪接因子(Clk1 和 Clk4)以及增殖和血管生成促进因子(Cyr61 和 flTF)的表达。A549 细胞中的 asTF 过表达也增加了细胞数量和管形成。这些作用是通过诱导 Cyr61、MCP-1 和 VEGF 以及整合素 α(v)β(3)介导的。总之,我们的结果表明,缺氧条件下 A549 肺癌细胞的促血管生成潜力通过 TF 异构体表达的调节来调节,而 TF 异构体表达的调节又受选择性剪接的控制。

相似文献

1
Regulation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells.缺氧诱导的人肺癌细胞中促血管生成组织因子表达的调控。
Oncol Rep. 2013 Jul;30(1):462-70. doi: 10.3892/or.2013.2413. Epub 2013 Apr 22.
2
Overexpression of alternatively spliced tissue factor induces the pro-angiogenic properties of murine cardiomyocytic HL-1 cells.组织因子剪接异构体的过表达诱导鼠心肌细胞 HL-1 的促血管生成特性。
Circ J. 2011;75(5):1235-42. doi: 10.1253/circj.cj-10-0783. Epub 2011 Mar 7.
3
Expression of flTF and asTF splice variants in various cell strains and tissues.flTF 和 asTF 剪接变异体在各种细胞株和组织中的表达。
Mol Med Rep. 2019 Mar;19(3):2077-2086. doi: 10.3892/mmr.2019.9843. Epub 2019 Jan 10.
4
Regulation and differential role of the tissue factor isoforms in cardiovascular biology.组织因子异构体在心血管生物学中的调控和差异作用。
Trends Cardiovasc Med. 2010 Aug;20(6):199-203. doi: 10.1016/j.tcm.2011.08.001.
5
Interplay between alternatively spliced Tissue Factor and full length Tissue Factor in modulating coagulant activity of endothelial cells.可变剪接的组织因子与全长组织因子在调节内皮细胞凝血活性中的相互作用。
Thromb Res. 2017 Aug;156:1-7. doi: 10.1016/j.thromres.2017.05.028. Epub 2017 May 25.
6
Alternatively spliced tissue factor induces angiogenesis through integrin ligation.可变剪接的组织因子通过整合素连接诱导血管生成。
Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19497-502. doi: 10.1073/pnas.0905325106. Epub 2009 Oct 29.
7
Alternatively spliced tissue factor promotes plaque angiogenesis through the activation of hypoxia-inducible factor-1α and vascular endothelial growth factor signaling.可变剪接的组织因子通过激活缺氧诱导因子-1α和血管内皮生长因子信号通路促进斑块血管生成。
Circulation. 2014 Oct 7;130(15):1274-86. doi: 10.1161/CIRCULATIONAHA.114.006614. Epub 2014 Aug 12.
8
Splice variants of Tissue Factor and integrin-mediated signaling.组织因子和整合素介导的信号转导的剪接变体。
Thromb Res. 2012 May;129 Suppl 2:S34-7. doi: 10.1016/j.thromres.2012.02.027. Epub 2012 Mar 17.
9
Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.血管内皮生长因子(VEGF)促血管生成和抗血管生成亚型的表达受剪接和生长因子的差异调节。
J Cell Sci. 2008 Oct 15;121(Pt 20):3487-95. doi: 10.1242/jcs.016410.
10
The role of tissue factor isoforms in cancer biology.组织因子异构体在癌症生物学中的作用。
Int J Cancer. 2015 Aug 1;137(3):497-503. doi: 10.1002/ijc.28959. Epub 2014 May 16.

引用本文的文献

1
Preclinical evaluation of radiolabeled tissue factor-targeted peptide for theranostics of hepatocellular carcinoma post percutaneous ethanol injection.放射性标记的组织因子靶向肽用于经皮乙醇注射后肝细胞癌诊疗的临床前评估
Theranostics. 2024 Oct 28;14(19):7370-7382. doi: 10.7150/thno.102130. eCollection 2024.
2
2-Desaza-annomontine (C81) impedes angiogenesis through reduced VEGFR2 expression derived from inhibition of CDC2-like kinases.2-去氮杂阿朴啡(C81)通过抑制 CDC2 样激酶来减少 VEGFR2 表达,从而抑制血管生成。
Angiogenesis. 2024 May;27(2):245-272. doi: 10.1007/s10456-024-09906-y. Epub 2024 Feb 26.
3
The role of alternative splicing in lung cancer.
剪接在肺癌中的作用。
Cancer Chemother Pharmacol. 2023 Aug;92(2):83-95. doi: 10.1007/s00280-023-04553-4. Epub 2023 Jun 19.
4
Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer.组织因子(凝血因子III):一种有望针对癌症进行靶向及重新靶向的潜在双刃剑分子。
Biomark Res. 2023 Jun 6;11(1):60. doi: 10.1186/s40364-023-00504-6.
5
Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy.肠道微生物群与肿瘤免疫逃逸:改善肿瘤免疫治疗的新视角
Cancers (Basel). 2022 Oct 28;14(21):5317. doi: 10.3390/cancers14215317.
6
Tumor Cell-Induced Platelet Aggregation as an Emerging Therapeutic Target for Cancer Therapy.肿瘤细胞诱导的血小板聚集作为癌症治疗的新兴治疗靶点
Front Oncol. 2022 Jun 23;12:909767. doi: 10.3389/fonc.2022.909767. eCollection 2022.
7
EPCR-PAR1 biased signaling regulates perfusion recovery and neovascularization in peripheral ischemia.EPCR-PAR1 偏向性信号调节外周缺血中的再灌注恢复和血管新生。
JCI Insight. 2022 Jul 22;7(14):e157701. doi: 10.1172/jci.insight.157701.
8
Intramuscular Expression of Plasmid-Encoded FVII-Fc Immunoconjugate for Tumor Immunotherapy by Targeting Tumoral Blood Vessels and Cells.通过靶向肿瘤血管和细胞,利用质粒编码的FVII-Fc免疫缀合物进行肿瘤免疫治疗的肌内表达
Front Oncol. 2021 May 24;11:638591. doi: 10.3389/fonc.2021.638591. eCollection 2021.
9
Beyond thrombosis: the impact of tissue factor signaling in cancer.超越血栓形成:组织因子信号在癌症中的影响。
J Hematol Oncol. 2020 Jul 14;13(1):93. doi: 10.1186/s13045-020-00932-z.
10
Therapeutic Antibody-Like Immunoconjugates against Tissue Factor with the Potential to Treat Angiogenesis-Dependent as Well as Macrophage-Associated Human Diseases.具有治疗血管生成依赖性以及巨噬细胞相关人类疾病潜力的抗组织因子治疗性抗体样免疫缀合物。
Antibodies (Basel). 2018 Mar;7(1). doi: 10.3390/antib7010008. Epub 2018 Jan 23.